Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.71 |
| ▸ | ITK | Q08881 | 4/20 | 0.71 |
| ▸ | SYK | P43405 | 4/20 | 0.65 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.54 |
| ▸ | BTK | Q06187 | 2/20 | 0.53 |
| ▸ | AURKA | O14965 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222113 | 0.89 | EGFR (0.68) | EGFRITKSYKPTK2SRC | |
| SCHEMBL1221703 | 0.89 | EGFR (0.68) | EGFRITKSYKPTK2LRRK2 | |
| SCHEMBL3663623 | 0.89 | EGFR (0.70) | EGFRITKSYKPTK2BTK | |
| SCHEMBL1221681 | 0.89 | SYK (0.70) | EGFRITKSYKPTK2SRC | |
| SCHEMBL1039543 | 0.87 | EGFR (0.58) | EGFRITKSYKPTK2SRC | |
| SCHEMBL1221887 | 0.87 | EGFR (0.66) | EGFRITKSYKPTK2SRC | |
| SCHEMBL12726303 | 0.86 | EGFR (0.65) | EGFRITKSYKPTK2SRC | |
| SCHEMBL1222061 | 0.86 | EGFR (0.65) | EGFRITKSYKPTK2SRC | |
| SCHEMBL1222074 | 0.86 | EGFR (0.65) | EGFRITKSYKPTK2BTK | |
| Hydrochloric Acid SCHEMBL1037848 | 0.85 | EGFR (0.64) | EGFRITKSYKPTK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | ZAP70, SYK, LCK | EGFR 2061/4885ITK 429/4885SYK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.